Skip to content

GeneDx Holdings WGS Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Natera, Inc. logo
Natera, Inc.NTRA
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
Quest Diagnostics logo
Quest DiagnosticsDGX
Revvity logo
RevvityRVTY
Labcorp Holdings logo
Labcorp HoldingsLH
Illumina logo
IlluminaILMN

Other financials

Income statement

See full
Revenue$102.3M+17.4%
Gross profit$68.2M+16.6%
Operating income-$57.5M-1,163%
Net income-$63.3M-870%
EPS (diluted)-$2.16-839%

Balance sheet

See full
Cash & equivalents$94.9M-5.7%
Total debt$96.7M+82.5%
Total equity$254.1M-1.3%
Total assets$506.3M+13.4%

Cash flow

See full
Operating cash flow-$32.4M-418%
CapEx$6.5M+5.3%
Free cash flow-$38.9M-1,059%

Valuation

See full
Market cap$1.72B-24.3%
Enterprise value$1.73B-22.8%
P/S3.9×-3.0×

Profitability

See full
Gross margin69.6%+4.3pp
Operating margin-14.9%
Net margin-17.6%
FCF margin3.8%+2.1pp

Returns & leverage

See full
Return on equity-30.4%
Debt / equity0.4×+0.2×
Current ratio3.1×-0.2×

Where this comes from

Reported directly by GeneDx Holdings in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: GeneDx Holdings’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about GeneDx Holdings's deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is GeneDx Holdings's deferred tax assets and other non-current assets?
GeneDx Holdings (WGS) reported deferred tax assets and other non-current assets of $4.28M in Q1 2026.
How has GeneDx Holdings's deferred tax assets and other non-current assets changed year-over-year?
GeneDx Holdings's deferred tax assets and other non-current assets increased by 0.7% year-over-year, from $4.25M to $4.28M.
What is the long-term trend for GeneDx Holdings's deferred tax assets and other non-current assets?
Over 5 years (2020 to 2025), GeneDx Holdings's deferred tax assets and other non-current assets has grown at a 3.7% compound annual growth rate (CAGR), from $3.6M to $4.32M.